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Alzheimer’s disease (AD) and osteoporosis are multifactorial progressive degenerative
disorders. Increasing evidence shows that osteoporosis and hip fracture are common
complication observed inADpatients, although themechanisms underlying this association
remain poorly understood. Reactive oxygen species (ROS) are emerging as intracellular
redox signalingmolecules involved in the regulation of bonemetabolism, including receptor
activator of nuclear factor-κB ligand-dependent osteoclast differentiation, but they also
have cytotoxic effects that include lipoperoxidation and oxidative damage to proteins and
DNA. ROS generation, which is implicated in the regulation of cellular stress response
mechanisms, is an integrated, highly regulated, process under control of redox sensitive
genes coding for redox proteins called vitagenes. Vitagenes, encoding for proteins such as
heat shock proteins (Hsps) Hsp32, Hsp70, the thioredoxin, and the sirtuin protein, represent
a systems controlling a complex network of intracellular signaling pathways relevant to life
span and involved in the preservation of cellular homeostasis under stress conditions.
Consistently, nutritional anti-oxidants have demonstrated their neuroprotective potential
through a hormetic-dependent activation of vitagenes. The biological relevance of dose–
response affects those strategies pointing to the optimal dosing to patients in the treatment
of numerous diseases. Thus, the heat shock response has become an important hormetic
target for novel cytoprotective strategies focusing on the pharmacological development of
compounds capable ofmodulating stress responsemechanisms. Herewe discuss possible
signaling mechanisms involved in the activation of vitagenes which, relevant to bone
remodeling and through enhancement of cellular stress resistance provide a rationale to
limit the deleterious consequences associated to homeostasis disruption with consequent
impact on the aging process.
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INTRODUCTION
Mitochondrial medicine is emerging as powerful candidate for
expanding anatomical and Mendelian biological concepts aimed
to solve complexity in age-related diseases, aging and cancer (Di
Domenico et al., 2010; Wallace, 2010, 2012, 2013). Interaction
between structure and energy is a fundamental life prerequisite.
This dualism in eukaryotic cell, was generated approximately
two billion years ago after the symbiosis of a glycolytic pro-
genitor, which evolved the nucleus–cytosolic compartment, and
an oxidative progenitor evolving toward an ancient mitochon-
drion. Initially each proto-organism contained all the genes for
an independent life. However, 1.2 billion years later, after sub-
sequent genomic reorganizations and alternative rearrangements,
was achieved a cellular arrangement in which the mitochondrial
compartment became specialized in the generation of energy,
while the nuclear and cytosolic compartment was functionally
polarized toward structure. This ﬁnal arrangement was the start-
ing point for multicellularity fostering evolution in higher plants
and animal kingdom, including humans. Notably, this original
architecture comeback powerfully in our cells in all conditions
where tumor initiation and promotion occur and the glycolytic
tone of metabolic potential put in motion a process leading to
the marginalization of energy transduction mechanisms, kicking
off mitochondrial energy production in favor of a sustained high
proliferative potential which underlie tumor progression (Cal-
abrese et al., 2007c; Wallace, 2008; Perluigi et al., 2010; Bellia et al.,
2011). In view of this, comprehension of aging mechanisms of
aging and determinants of life span will contribute to decrease
age-related morbidity and promote healthy aging. Over the last
centuries, as a consequence of exogenous environmental factors
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and medical progress, average lifespan has increased, but maximal
life span has not changed (Edrey et al., 2014; Willcox and Will-
cox, 2014). Consistent with this notion and relevant to longevity
mechanisms, vitagenes by preserving cellular homeostasis dur-
ing stressful conditions represent a functional network regulating
life span. Vitagenes, are redox sensitive genes encoding for heat
shock proteins (Hsps) Hsp32, Hsp70, for the thioredoxin and
the sirtuin protein systems (Calabrese et al., 2008e; Bellia et al.,
2009; Cornelius et al., 2013b). In this regard, nutritional anti-
oxidants, have recently been demonstrated to be neuroprotective
via hormetic pathways, including vitagenes. The hormetic feature
of dose–response appears to quantitatively describe the limits of
biological plasticity across phyla as well as at different levels of
biological organization (cell, organ, and organism). Thus, phar-
maceutical treatments for a wide range of human conditions can
be based upon the hormetic biphasic dose response, as discovered
within preclinical evaluations and then directly applied to human
populations. The biological relevance of hormetic dose–response
affects, ultimately, those strategies pointing to the optimal dos-
ing to patients in the treatment of numerous diseases and, within
this context, the heat shock response (HSR) can be considered an
important hormetic target to design cytoprotective compounds
able of inducing stress response mechanisms. Here we discuss
signaling mechanisms activating vitagenes, which are relevant to
bone remodeling which, through enhancement of stress resistance
provide a rational therapeutic approach to limit the deleterious
consequences associated to disruption of homeostasis with con-
sequent impact on the aging process (Murshid et al., 2013; Saibil,
2013).
ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) is characterized by progressive deterio-
ration of cognitive functions and stress (Calabrese et al., 2006d),
with biochemical alterations consisting in the accumulation of
amyloid-β (Aβ) protein in the form of senile plaques and intracel-
lular neuroﬁbrillary tangles, associated with hyperphosphorylated
tau protein and neuronal cell depletion (Liu and Chan, 2014).
Prevalence of AD rises exponentially with age, increasing drasti-
cally after 65 years. Sporadic AD, affecting more than 15 million
people worldwide, is more common than familial AD (Richard
and Brayne, 2014). Mild cognitive impairment (MCI) is regarded
as a transition state between normal aging and dementia (Swom-
ley et al., 2013). Importantly, almost one half of these individuals
evolves to late onset AD (LOAD), accounting for about 60% of
the total cases of dementia in USA and Western countries (Swom-
ley et al., 2013). MCI, which can also be due to severe depression,
extensive white matter pathology or severe vitamin B12 deﬁciency,
is characterized by memory impairment with or without com-
promission in other single or multiple cognitive domains, in the
absence of fulﬁllment of the standardized criteria for dementia
(Swomley et al., 2013). The pathological hallmarks of AD are
amyloid plaques, formed of Aβ peptide derived from the trans-
membrane amyloid precursor protein (APP; Siciliano et al., 2011),
and neuroﬁbrillary protein tangles, composed of hyperphospho-
rylated tau, in the temporal lobe and some other brain cortical
regions associated with death of neuronal cells and synaptic deple-
tion (Hardas et al., 2013). Given the heterogeneity of the etiologic
factors underlying the pathophysiology of AD,although integrated
approaches have been elaborated to explain its pathogenesis, such
as Aβ aggregation, the precise deﬁnition of most critical fac-
tors determining the clinical onset and progression of the disease
remains and elusive and a difﬁcult task (Siciliano et al., 2011).
Aβ peptide (Lodi et al., 2006; Wallace, 2013) has been shown
to induce protein oxidation in both in vitro and in vivo studies
(Hardas et al., 2013), and increasing evidence supports the role
of free radical reactions in the pathogenesis of the disease. Con-
sistent with this notion, it is demonstrated that these peptides
form oligomers exerting neurotoxic effects by enhancing reac-
tive oxygen species (ROS) level in the brain (Hardas et al., 2013).
More speciﬁcally, Aβ oligomers directly generate H2O2 through:
(i) a cupper-dependent superoxide dismutase-like activity (Fang
et al., 2010), (ii) activation of NADPH-oxidase in astrocytes,
(iii) modulation of mitochondrial ROS generation via regulation
of activity of enzymes such as Aβ-binding alcohol dehydrogenase
and α-ketoglutarate dehydrogenase (Borger et al., 2013). Increased
proteotoxic and lipoperoxidative brain damage has been docu-
mented in subjects with MCI, compared to normal (Chico et al.,
2013; Swomley et al., 2013; Cervellati et al., 2014). Thus, oxidative
stress and disturbed protein metabolism and their interaction in
a vicious cycle characterize AD as a protein misfolding disease,
with protein clearance defects through the ubiquitin-proteasome
system (Hong et al., 2014; Valasani et al., 2014). There is strong
evidence, also, that APP may act as a trophic factor relevant to
neurite outgrowth and synaptogenesis, as well as growth and cell
proliferation (Abramov et al., 2009; Jiang et al., 2013; Bukanova
et al., 2014; Dawkins and Small, 2014; Hughes et al., 2014). How-
ever, future research are required to fully clarify mechanisms of
APP action (Dawkins and Small, 2014). In addition, identiﬁcation
of normal physiological functions of Aβ is an extremely impor-
tant emerging issue, as many therapeutic strategies used for the
treatment of AD point to prevent Aβ production or to increase
Aβ clearance from the brain. Consistently, it cannot be, so far,
ruled out that these strategies does not interfere with important
physiological functions (Abramov et al., 2009; Kang et al., 2013;
Bukanova et al., 2014; Mizoi et al., 2014; Ponnayyan Sulochana
et al., 2014).
Among biochemical alterations occurring in AD pathology,
deﬁcit in choline esterase and overstimulation of NMDA receptors
are the main target for current therapeutic approaches focusing on
symptoms rather than more substantial eradication of the disease.
Thus, to date there not drugs are available in the market capable of
revert the disease, but only to inﬂuence the intensity of symptoms
and the progression of the pathology (Ponnayyan Sulochana et al.,
2014).
CELLULAR STRESS RESPONSE AND THE VITAGENE
NETWORK
It is known that low concentrations of ROS are able to induce
the expression of anti-oxidant enzymes and other defense mech-
anisms. The basis to explain this phenomenon refers to the
concept of hormesis (Calabrese et al., 2006b), which is a dose–
response relationship in which a given substance is stimulatory
at low dose while at high doses exerts inhibitory effects. Radi-
cal active species may be beneﬁcial since they act as signals to
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enhance cellular defenses but become deleterious when present
within a cells at high levels. ROS when in excess can over long-
term disrupt redox homeostasis, cause oxidative stress, loss of
molecular ﬁdelity which underlie accumulation of unfolded or
misfolded proteins in brain. Alzheimer’s, Parkinson’s, Hunt-
ington’s, amyotrophic lateral sclerosis, and Friedreich ataxia
all belong to the so called “protein conformational diseases”
affecting several thousands of aged people in all the world
(Lodi et al., 2006). Unfolded protein response put in motion
by chaperons actively rescue misfolded proteins, breaking up
aggregates, and assisting the refolding process. Those proteins
that cannot be rescued by refolding are, however, delivered
to the proteasome by other chaperones and recycled (Lodi
et al., 2006). In general, an unfolded protein response occur
within conformational diseases characterized by dysfunctional
aggregation of proteins accumulating in a non-native confor-
mation. Under these physiopathological conditions, multiple
metabolic derangements generally take place in association to
excessive production of ROS and oxidative stress (Lodi et al.,
2006).
The ability of a cell to withstand stressful conditions is
deﬁned cellular stress response (Figure 1). This phenomenon
includes the HSR and represents a highly conserved ancient
mechanism of cytoprotection (Calabrese et al., 2006b; Lodi et al.,
2006). Synthesis of Hsps, which includes protein chaperones, is
fundamental for proper folding and repair of denatured pro-
teins, thus promoting conditions favorable to cell survival that
would otherwise result in apoptotic cell death (Calabrese et al.,
2006c; Scapagnini et al., 2006). Chaperones promote cell sur-
vival by sequestering damaged, denatured proteins and inhibiting
formation of aggregates. The response to formation of aggre-
gates is coordinated by an elaborated regulatory system which,
simultaneously to up-regulation of several chaperones and other
survival-promoting proteins, silences most cellular highly energy
demanding functions. For this reason, most chaperones are
also deﬁned Hsps in reference to heat shock as the prototypic
form of cellular stress. Chaperones under normal conditions
elicit multiple roles, promoting proteins or RNA transport and
remodeling events in large protein complexes essential for the
regulation of cell migration, differentiation, signaling, tran-
scription, and proliferation. Cellular stress response consist of
pro-survival pathways controlled by cytoprotective genes called
vitagenes (Mancuso et al., 2007b), resulting in the production
of molecules endowed with anti-oxidant and anti-apoptotic
potential, such as Hsps, glutathione, bilirubin (BR), and car-
bon monoxide (CO; Calabrese et al., 2007a). Vitagenes include
members of the Hsp family, such as heme oxygenase-1 and
Hsp72, sirtuins and the thioredoxin/thioredoxin reductase sys-
tem (Calabrese et al., 2008d). Increasing evidence suggests that the
HSR promotes cytoprotective conditions in several human dis-
ease states, such as mild chronic inﬂammation, cancer, aging,
and neurodegenerative diseases (Calabrese et al., 2007b, 2008e,
2011). Thus, an emerging interest is growing on the cytopro-
tective potential of the HSR as pharmacological agents capa-
ble of inducing the HSR are important candidate for novel
anti-degenerative and anti-inﬂammatory therapeutic strategies
FIGURE 1 |Vitagenes and the pathway of cellular stress response.
Misfolded proteins cumulating in response to proteotoxic stresses trigger
the cellular stress response. Hsps that are normally bound to HSF1,
maintaining it in a repressed state before stress, are titrate away by
damaged or misfolded proteins with resulting HSF-1 activation. Multi-step
activation of HSF1 involves post-translational modiﬁcations, such as
hyperphosphorylation, deacetylation, or sumoylation, which allow HSF1 to
trimerize, translocate into the nucleus, and bind to heat shock elements
(HSEs) in the promoter regions of its target Hsp genes. Nutritional
anti-oxidants, are able to activate vitagenes, such as heme oxygenase,
Hsp70, thioredoxin reductase and sirtuins which represent an integrated
system for cellular stress tolerance. Activation of vitagene system, with
up-regulation of HO-1, thioredoxin, GSH, and sirtuin, results in reduction of
pro-oxidant conditions. During inﬂammaging, including aged-associated
pathologies, such as Alzheimer’s disease and osteoporosis, a gradual
decline in potency of the heat shock response occur and this may prevent
repair of protein damage, leading to degeneration and cell death of critical
parenchymal cells.
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(Abdul et al., 2006; Mancuso et al., 2007a; Calabrese et al.,
2008b,g,j).
Transcriptional, translational, and post-translational regula-
tion of cellular stress response occur with the intervention of heat
shock transcription factors (HSFs) normally expressed and main-
tained in an inactive state (Calabrese and Maines, 2006; Perluigi
et al., 2006; Calabrese et al., 2008f,h; Zhang et al., 2014). Post-
translational regulation of HSFs is an emerging area of interest
integrating the metabolic state of the cell with biology of stress,
and hence controlling important complex aspects of proteome
molecular ﬁdelity and physiology with consequent impact on
aging processes. The HSR is transcriptionally controlled through
cis-acting sequences called heat shock elements (HSEs) present
in multiple copies upstream of the Hsp genes. Unlike inverte-
brates showing a single HSF, vertebrates express multiple HSFs
as for plants. Four mammalian members of HSF have been
identiﬁed: HSF1, HSF2, HSF3, and HSF4, all recognizing and
binding the HSE, formed by inverted repeats of nGAAn consen-
sus sequences. Thus, all four HSFs have overlapping functions
associated with distinct patterns of tissue-speciﬁc expression, and
undergo multiple post-translational modiﬁcations and exhibit-
ing various interacting protein partners. Up-regulation of Hsp
synthesis in response to stress, besides heat shock, is also initi-
ated by redox-dependent mechanisms, endogenous or exogenous,
in both cases resulting in trimerization and DNA binding of
HSF1. Relevant to transactivation process is the cysteine moi-
ety which operates as critical redox switch leading to the HSF
activation (Zhang et al., 2014). In particular, formation of an
intermolecular disulﬁde bond between cysteine 36 and cysteine
103 within HSF1, trigger trimerization and subsequent DNA
binding, whereas a disulﬁde intramolecular bond formation has
inhibitory effects for the transactivating activity of HSF. Con-
sistent with this notion, modulation of HSF-mediated gene
regulation has an emerging pharmacologic potential, as small-
molecule with the capability of activation or inhibition of HSFs,
can exert important inﬂuence on aging, neurodegenerative pro-
cesses and longevity mechanisms (Fujimoto et al., 2010; Zhang
et al., 2011; Akerfelt et al., 2012; Westerheide et al., 2012). The
regulatory domain of HSF has competence to sense heat shock,
however, its induction is post-translationally controlled (Fuji-
moto et al., 2010; Akerfelt et al., 2012; Westerheide et al., 2012).
In normal non-stressed cellular conditions, HSF1 is maintained
inactive and in amonomeric state through interactionwithHsp90.
Thus, pharmacological inhibition of Hsp90 results in a conversion
of monomeric HSF1 in a trimerized HSF1 with DNA-binding
competence (Calabrese et al., 2008c,i, 2009a,b,d). Trimerization,
nuclear translocation and interactionwithHSE in theDNArapidly
declines in cells soon after proteotoxic insult exposure, since
HSF1 binding to the promoter occurs within seconds, reach-
ing in about 1 min saturation with the contribution of other
components such as a ribonucleoprotein complex containing the
eukaryotic elongation factor 1A and a constitutive non-coding
RNA, heat shock RNA-1 (HSR-1) endowed with heat-sensing
capability (Calabrese et al., 2009c, 2010g,h). According to the most
accreditedmodel, in response to heat shockHSR-1 undergoes con-
formational changes facilitating HSF1 trimerization. Under this
transactivating conditions, HSF1 is post-translationally modiﬁed
through phosphorylation, sumoylation, and/or acetylation (Cal-
abrese et al., 2010d, 2011). Increasing evidence suggests that
phosphorylation and sumoylation of HSF1 is a phenomenon
occurring rapidly after heat shock, while acetylation occurs with
a delayed kinetics in coincidence of the attenuation phase of
the cycle of HSF1 activation. In particular, acetylation of HSF1
is a process regulated by the ratio of acetylation/deacetylation
controlled by p300–CBP (CREB-binding protein) and by the
NAD+-dependent sirtuin, SIRT1. With respect to this, enhanced
DNA-binding activity of HSF1 ensues after increased expression
and activity of SIRT1, whereas acetylation of HSF1 consequent
to down-regulation of SIRT1 reduces DNA-binding activity with
no effect on the trimerization process (Calabrese et al., 2010d).
Increasing evidence indicates the involvement of SIRT1 in caloric
restriction and aging, as demonstrated in senescent cells where
the age-dependent loss of SIRT1, associated to impairment in
HSF1 activity, correlate with attenuation of the HSR and dis-
ruption of proteostatic mechanisms, thereby linking HSR to
nutrition and aging (Calabrese et al., 2010e,f; Di Paola et al.,
2011).
Keap1/Nrf2/ARE BIOLOGY AND THE HEME OXYGENASE
PATHWAY OF STRESS TOLERANCE
HSF1 is a central regulator in the gene expression of Hsps,
however, in addition to thismechanismcontrolling vitagenes coor-
dination, a response protecting against various electrophiles and
oxidants operates integrating cytoprotection as“phase 2 response,”
known also as “the electrophile counterattack response” (Zhang
et al., 2011, 2014). Phase 2 response proteins include heme oxy-
genase 1, thioredoxin, and thioredoxin reductase, all of which
can be up-regulated by the transcription factor Nrf2 (nuclear
erythroid 2-related factor 2), similarly to other cytoprotective
proteins, includingNAD(P)H:quinone oxidoreductase 1 (NQO1),
γ-glutamylcysteine synthetase, glutathione reductase, glutathione
transferases (GST),UDP-glucuronosyltransferase, epoxide hydro-
lase, aldo-keto reductases, ferritin, and glutathione conjugate
efﬂux pumps (Zhang et al., 2011, 2014). The elaborate network
of Nrf2-dependent phase 2 response proteins enable eukaryotic
cells to counteract the damaging effects associated to oxidants
and electrophiles, agents primarily involved in the pathogenesis
of neurodegenerative disorders, atherosclerosis, aging, and cancer
(Zhang et al., 2011, 2014). A major factor operating in the con-
trol of the expression of these proteins is the Keap1/Nrf2/ARE
system. Activation of gene expression requires that Nrf2, a basic
leucine zipper transcription factor, binds in the upstream regu-
latory regions of these genes containing single or multiple copies
of the anti-oxidant/electrophile response elements (ARE, EpRE).
Nrf2 binding to the ARE occur in heterodimeric combinations
with members of the small Maf family of transcription factors.
Under normal conditions the pathway operates at basal levels
controlled by a cytosolic protein with function of repressor, the
Kelch-like ECH-associated protein 1 (Keap1). When Keap1 is
bound to Nrf2, the latter is presented, by binding to the E3
ubiquitin ligase Cullin3–RING box1 (Cul3–Rbx1), to the ubiq-
uitin system for proteasomal degradation. At least 10 distinct
chemical classes of inducers of the Keap1/Nrf2/ARE pathway, are
known and belong to: (i) Michael acceptors (oleﬁns or acetylenes
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conjugated to electron-withdrawing groups); (ii) isothiocyanates;
(iii) oxidizable diphenols, quinones, and phenylenediamines; (iv)
thiocarbamates; (v) trivalent arsenicals; (vi) dithiolethiones; (vii)
hydroperoxides; (viii) vicinal dimercaptans; (ix) heavy metals;
and (x) polyenes. All these members share the common prop-
erty of presenting chemical reactivity toward sulfhydryl groups
through oxido-reduction, alkylation, or disulﬁde interchange
mechanisms (Calabrese et al., 2010d, 2011; Zhang et al., 2011,
2014).
Heme oxygenase is a sensors of oxidative stress within cells
modulating redox status and homeostasis. Heme oxygenase-1, an
Hsp32, protects against oxidative damage converting pro-oxidant
heme into biliverdin, free iron, and CO. With the interven-
tion of the enzyme biliverdin reductase (BVR) biliverdin is then
reduced by into BR, a linear anti-oxidant tetrapyrrole (Cal-
abrese et al., 2010d). BR has been demonstrated efﬁciently buffer
nitrosative stress, owing to its capability to bind and inactivate
NO-derived RNS (Pennisi et al., 2011; Scapagnini et al., 2011).
Two HO isoforms are known: an inducible isoform, HO-1 and
HO-2 which is a constitutive enzyme (Calabrese and Maines,
2006). These isoforms share only 43% homology being products
of different genes. HO-1 and HO-2 present important differ-
ences in cell and tissue regulation and distribution (Mancuso
et al., 2006, 2008). Moreover, only in rat as third protein, HO-3
has been found to be retrotransposomal product of the HO-
2 gene (pseudogene). In spite of playing the same enzymatic
role, HO-1 and HO-2 have different protective function in tis-
sues. HO-1 induction occurs as early response to oxidative insult
resulting rapid transformation of heme into CO and BR. On
the contrary, constitutive HO-2, regulates heme homeostasis a
function associated within a cell with the sensing of intracellu-
lar levels of CO. HO-1, is induced in response to oxidative and
nitrosative stress, heme, Aβ, dopamine analogs, H2O2, hyper-
oxia, UV light, heavy metals, prostaglandins, NO, peroxynitrite,
Th1 cytokines, oxidized lipid products, and lipopolysaccharide,
as well as growth factors. In all these conditions, the ARE con-
tained in its promoter region, is central to its redox regulation
(Alam and Cook, 2007; Calabrese et al., 2012b), recognizing two
upstream enhancers, E1 and E2 where multiple ARE elements
are contained. Consistently, polymorphisms in the lengths of GT
repeats (Calabrese et al., 2011; Pennisi et al., 2011; Scapagnini
et al., 2011) within the ho-1 promoter is critical for the expres-
sion and functions of HO-1 in humans. Higher HO-1 activity
is associated with the short-GT polymorphisms, a conditions
thought be protective against oxidant disorders (e.g., coronary
artery disease, atherosclerosis-linked conditions), whereas long
GT sequences, coding for a relatively unstable, Z-conformational
DNA, exhibits reduced transcriptional activity, as well as basal
and stimulated HO-1 protein levels, as found in various malig-
nant conditions (Calabrese et al., 2010d). Overexpression of HO-1
results in increased cGMP and bcl-2 levels in neurons, inactivation
of p53, up-regulation of anti-oxidant proteins as well as ferritin
which sequesters and inactivates free iron (Alam and Cook, 2007;
Calabrese et al., 2012b). Although large consensus exists on the
fact that increased HO-1 expression is a protective mechanism
operating under oxidative stress conditions, however, there is evi-
dence that HO-1 can be repressed during the same conditions,
particularly during hypoxia. HO-1 repression under this con-
dition is sustained by the heme-regulated transcription factors
Bach1/Bach2 (Calabrese et al., 2010d, 2011) and it has been argued
that this might be necessary to reduce the energy request due
to heme degradation, to limit formation of CO and BR which
can accumulate to toxic levels, and to increase heme availabil-
ity for proper mitochondrial respiration (Calabrese et al., 2006c,
2008g). Neurodegeneration as a chronic inﬂammatory oxida-
tive condition caused by Aβ metabolic disruption, makes HO-1
an important target for therapeutic anti-inﬂammatory strategies.
HO-1 mRNA and protein expression have been documented to
be increased in AD brain, in association with neuroﬁbrillary
tangles. This ﬁnding may have the biological meaning of a pro-
tective response in vulnerable neurons to transform pro-oxidant
heme into BR and CO,whose anti-oxidant and anti-inﬂammatory
nature has been ascertained. This opens new therapeutic avenue,
as polyphenols contained in herbs and spices can represent poten-
tial drugs for the prevention and treatment of AD (Scapagnini
et al., 2006; Calabrese et al., 2007a,2008b). Epidemiological studies
have demonstrated that curcumin is responsible for the signiﬁ-
cantly reduced (4.4-fold) prevalence of AD in India, compared
to United States (Calabrese et al., 2007b, 2008b; Mancuso et al.,
2007a), and curcumin given chronically in the diet to transgenic
APPSw, a mouse model (Tg2576) of AD suppresses brain inﬂam-
matory and oxidative damage, an effect associated to inhibition
of nuclear factor-κB (NF-κB) and efﬁcient prevention of neu-
ronal cell death (Calabrese et al., 2009b,d, 2010d,h; Gupta et al.,
2011).
HORMESIS
Hormesis is a dose–response phenomenon, characterized by
a low-dose stimulation and a high-dose inhibition. The term
hormesis was ﬁrst introduced into the scientiﬁc literature in 1943
by Chester Southam and John Ehrlich, mycology researchers
at the University of Idaho, who reported that low concen-
trations of extracts from the Red Cedar tree enhanced the
metabolism of a number of fungal species. The term horme-
sis was derived from the Greek meaning to excite. Prior to the
report of Southam and Ehrlich (1943), there was a substance
history of reports in the biological literature on also demon-
strating a similar biphasic dose response. It was ﬁrst reported
by Schulz who found that low concentrations of numerous dis-
infectants stimulated metabolism at low concentrations while
being inhibitory at higher concentrations (Schulz, 1887, 1888).
The research of Schulz was conﬁrmed by other investigators
and extended to other biological models and agents, with par-
ticular emphasis on bacteria, fungi, and plants over the next
several decades. The phenomenon was initially referred to as
the Arndt-Schulz Law and Hueppe’s Rule, with these terms
being subsequently replaced by the term hormesis. The occur-
rence of hormetic dose responses from the time of Schulz up
to approximately 1950 has been summarized in depth for both
chemical and radiation induced hormesis (Calabrese and Baldwin,
2000a,b,c,d,e).
Despite the fact that the hormesis concept has considerable
historical literature supporting its occurrence and reproducibility,
it failed to gain traction within the biomedical community due
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to the fact that Schulz inappropriately claimed that he had dis-
covered the explanatory principle of homeopathy, based on his
biphasic dose response with yeast (Calabrese, 2005). This procla-
mation led to strong disputes with medically oriented researchers
principally due to the long and intense conﬂict between home-
opathy and traditional medicine. In fact, a considerable effort
by leading pharmacologists of the Schulz era, such as Alfred
J. Clark, devoted considerable effort to criticize Schulz and his
biphasic dose response and to try to link it with high dilution
homeopathy, in an effort to marginalize and discredit homeopa-
thy (Calabrese, 2011). In addition to such historical antipathies,
the concept of hormesis was also difﬁcult to prove scientiﬁcally
as it required a substantial number of doses, especially in the
low dose zone, reasonably high statistical power, and biologi-
cal model systems with generally low variability and the strong
capacity for replication of ﬁndings. These factors are important
since the low dose stimulation is modest, with most maximum
stimulatory responses only being about 30–60% greater than the
unexposed control group (Figure 2). Thus, trying to test hormetic
hypotheses requires far more rigorous study designs and more
resources than was usually the case in hazard assessment type
investigations.
As a result of the historical conﬂicts between homeopathy
and traditional medicine and the inherent challenges in testing
hormetic hypotheses, the concept of hormesis never became well
established as a scientiﬁc concept in throughout most of the
twentieth century (Calabrese, 2008d). However, since the late
1970s there has been a multi-disciplinary-based resurgence of
the hormesis concept, based largely on technical improvements
in the capacity to measure at lower concentrations, advances in in
vitro and high throughput researchwhich has facilitated the capac-
ity to test a wide range of concentrations in an efﬁcient manner,
the development of mechanistic understandings of biphasic dose
responses especially at the receptor and cell signaling pathways lev-
els and the dose response andmechanistic linkage of developments
in the area of adaptive responses, including that of preconditioning
with hormesis (Calabrese, 2010).
Within recent years substantial hormetic dose response data
bases have been developed based on rigorous a priori entry and
evaluative criteria providing documentation for the hormetic dose
responses (Calabrese andBlain, 2005, 2009, 2011). These databases
provide strong evidence that hormetic dose responses are inde-
pendent of biological model, endpoint measured, the chemical
class of the inducing agent, the level of biological organization
(i.e., cell, organ, organism) and mechanism (Calabrese, 2013d).
These databases have conﬁrmed and far more ﬁrmly established
the quantitative features of the hormetic dose response, reveal-
ing that it represents a modest stimulation, usually less than twice
the value of the control group. It has also been established that
the hormetic dose response is typically reported for highly inte-
grated endpoints, especially those relating to cell proliferation,
complex behaviors, adaptive/preconditioning responses, repro-
ductive endpoints such as fecundity, cancer, mutation, cancer
endpoints, and longevity/aging. Detailed evaluations of the phar-
maceutical literature have also revealed that entire drug classes
are based up the hormetic dose responses. For example, preclin-
ical studies in the areas of anxiolytic drugs (Calabrese, 2008b),
anti-seizure drugs (Calabrese, 2008e), memory enhancing agents
(Calabrese, 2008a), drugs treating osteoporosis (Calabrese, 2008c),
and others typically demonstrate hormetic dose responses. Since
FIGURE 2 |The hormesis (biphasic) dose–response curve: generalized
quantitative features. The hormetic dose response is characterized by
speciﬁc quantitative features concerning its amplitude and width. Based on
more than 10,000 hormetic dose responses in various hormetic databases,
approximately 80% have their maximum response less than twofold
greater than the control. The strong majority of hormetic dose responses
extend over approximately a 5- to 10-fold dose range immediately below
the estimated response threshold. The hormetic dose response may occur
either as a result of a direct stimulation or as an overcompensation
response following an initial disruption in homeostasis, in both cases being
the quantitative features similar. The hormetic response appears to
quantitatively describe the limits of biological plasticity across phyla as well
as at different levels of biological organization (cell, organ, and organism).
The quantitative features of the hormetic dose response are also
independent of mechanism. Pharmaceutical treatments for a wide range of
human conditions are based upon the hormetic biphasic dose response as
discovered within preclinical evaluations and then directly applied to human
populations.
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it is now believed that the modest hormetic stimulation is a mea-
sure of biological plasticity it suggests that the hormetic dose
responses describes the degree to which pharmaceutical agents can
enhance biological performance (Calabrese and Mattson, 2011;
Calabrese, 2013a). It is important to note that during the entire
twentieth century the biomedical and regulatory communities
never validated the capacity of the threshold dose response to
make accurate predictions below the threshold, that is, the area
of the dose response where most people spend the majority of
their time. This lead to a series of direct, head-to-head compar-
isons between the threshold, linear and hormetic dose response
models using multiple large and independent dose response data
sets with multiple models, endpoints and agents (Calabrese and
Baldwin, 2001, 2003; Calabrese et al., 2006a, 2008a, 2010a). In
each of these assessments, the hormetic dose response signif-
icantly out-performed the threshold and linear dose response
models.
Major comprehensive evaluations of the biomedical litera-
ture have revealed that hormesis dose responses are commonly
reported in essentially all areas of research including the immune
system, tumor cell biology, neuroscience, including memory,
stress, anxiety, seizure, pain, numerous degenerative diseases,
wound healing and for a very broad range of receptor systems
and peptides (Calabrese, 2013b). The applications of the hormesis
dose response are therefore extensive, affecting drug discovery,
drug development, and the design of the clinical trial. Fur-
thermore, even areas such as preconditioning are based on the
hormetic concept (Calabrese et al., 2010b,c, 2012a, 2013; Cal-
abrese and Calabrese, 2013a,b; Krenz et al., 2013). This may be
seen in numerous studies which have assessed a wide range of
graded preconditioning doses with results being reﬂective of the
biphasic-hormetic dose response. The historical assessment of the
dose response has revealed that the dose response model that
was once rejected by the biomedical community about a cen-
tury ago is now the dose response model that has repeatedly
outcompeted the traditional doses responses models in direct
comparisons. It is the dose response model that has provided
quantitative insight into the magnitude of biological plasticity
and the theoretical basis for it. The hormetic dose response
thus underlines the basis of pharmaceutical strategies aimed at
enhancing biological performances in a broad range of scientiﬁc
areas.
BONE REMODELING, REDOX STATE, AND Aβ METABOLISM
Osteoporosis is a devastating disease having enormous health and
economic impacts, particularly considering the global shift toward
an aging population, characterized by a systemic and progressive
skeletal pathology characterized by compromised bone mineral
density and strength with the increased occurrence of fractures.
Despite rapid progress in our understanding over recent years,
patientmorbidity andmortality resulting from this disease are still
too high (Ono et al., 2014), and there is an urgent need for a proper
assessment of the underlying mechanisms and the development of
new treatment strategies to address this pathophysiological issue.
Patients with AD show signiﬁcantly increased risk of osteoporotic
hip fractures. However, whether abnormal Aβ peptide (Aβ) depo-
sition also occurs in osteoporosis and the relationship between
Aβ and human osteoporosis remains an open, not elucidated,
question (Li et al., 2014).
Amyloid-β peptide, one of the pathological hallmarks of AD, is
a small (40–42 amino acids) proteolytic fragment of a glycosylated
integral membrane cell surface receptor protein called APP and is
encoded by a gene on human chromosome 21 (Liu and Chan,
2014; Richard and Brayne, 2014). Aβ has attracted much attention
for its associationwith various pathologies (Stefanova et al., 2014).
Besides AD, Aβ plays a crucial role in other important neurode-
generative diseases, such as Huntington’s, Parkinson’s, and prion
disorders, as well as amyotrophic lateral sclerosis as well as type
2 diabetes and the most common age-related muscle disease of
inclusion body myositis (Tóth et al., 2014). Thus, APP/Aβ seems
to be associated with multiple degenerative disorders. Epidemio-
logical studies showed that patients with AD had an increased risk
of developing osteoporotic hip fractures even after considering the
increased frequency of fallings in AD patients (Xia et al., 2013),
suggesting one or more common denominators between both
disorders. Nevertheless, an association between Aβ and human
osteoporosis has not yet been clearly established, and also it has
been inferred that Aβmay be of physiological importance for sur-
vival of cells (Li et al., 2014). ExcessiveAβ aggregates and ﬁbrillates
to form amyloid plaques in the brain, thus leading to the exacer-
bation of AD pathology. Previous studies have identiﬁed a role for
Aβ in the activation of osteoclasts through gene knockout exper-
iments and use of the transgenic AD mouse model, Tg2576 (Li
et al., 2014). However, whether a large amount of Aβ deposits
also occur in osteoporotic bone tissues and the role human Aβ
may play on OC activation remain unclear. In addition to having
an activation effect on osteoclasts, Aβ may accumulate abnor-
mally in osteoporotic bone and play an important pathogenic
role. A close relationship between Aβ and osteoporosis is shown
across species from rodent to human, as demonstrated in differ-
ent clinical conditions in patient samples as well as in various
animal model and cell cultures. AD and osteoporotic hip frac-
tures often coexist during aging. Platelets have been shown to be
the primary source (90%) of Aβ in human blood with plasma
Aβ levels ﬂuctuating over time among individuals (Roher et al.,
2009). Besides human plasma and cerebrospinal ﬂuid, soluble
Aβ is also a component of human urine in Alzheimer’s. Despite
this level of knowledge surrounding APP and Aβ expression in
many tissues, reports on the expression and distribution of Aβ
in bone tissues and osteocytes remain an emerging evidence. Aβ
deposition has been found on the endosteal and periosteal sur-
faces of adult rat ulnae (Li et al., 2014). Notably, occurrence of
Aβ and APP abnormal accumulation in different tissues supports
the hypothesis that Aβ diseases may be a systemic disease, sug-
gesting that these malfolded proteins may either be produced
locally in diverse organs or may originate from a common cir-
culating precursor. Consistent with this notion, abnormal Aβ
and APP burden has been detected in osteoporotic bone tissues
from both human and rat OVX models, where Aβ42 was iden-
tiﬁed mainly in the membrane and cytoplasm of osteocytes and
extracellular matrix, while APP largely found in the membrane
of osteocytes. Despite increasing research efforts, still the mech-
anism underlying the accumulation of Aβ and APP in osteocytes
in osteoporotic bones remains elusive. One possible source for
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Aβ deposition in bone may be blood, where Aβ increases dur-
ing senescence (Li et al., 2014). In addition to this, secretion of
Aβ by mature osteoblasts has been documented, in agreement
with the ﬁnding of Aβ42 and APP formation in osteoblasts from
both human and OVX rats osteoporotic bone. In these condi-
tions, APP has been found to be able of suppressing osteoblast
differentiation, associated with osteoporotic alterations (Xia et al.,
2013). Given that osteoblast is the precursor of the osteocyte,
it is conceivable that the deposition of Aβ and APP in osteo-
cytes can be consequence of secretion by osteoblasts during both
osteogenic differentiation and aging processes. In turn, accumu-
lating Aβmay promote apoptotic process in osteocytes, likewise in
neurons thus determining bone loss and osteoporosis (Cui et al.,
2011). An interesting and controversial question concerns why
the abundant presence of proteins of Aβ abnormal metabolism in
the bone of osteoporotic patients did not cause them to develop
brain degeneration, such as AD. A number of explanations may
exist to provide a possible rationale. First, bone is a very special
organ, with limited blood supply, with most of the osteocytes
embedded in the matrix without direct contact with blood. In
these conditions, release of Aβ into the blood stream is not an
easy process. Second, the blood–brain-barrier (BBB) permeability
can be of extreme importance for the prevention of Aβ invasion
into the brain tissues, as uptake of peripheral Aβ by the brain is
not a normal occurrence without BBB compromission (Jefferies
et al., 2013). Lastly, both osteoporosis and AD are multifactorial
diseases with complex etiology and pathogenesis (Rachner et al.,
2011). Aβ deposits are present in several tissues, which indicates
that the protein may originate as product of local metabolism in
various organs or, similarly to other amyloidoses, can derive from
a circulating precursor common to all these pathophysiological
conditions. However, further studies are necessary to explore these
dynamics and understand the underlying mechanisms. Abnormal
Aβ deposition in osteoporotic bone tissues and its potent enhance-
ment effect on osteoclast differentiation and activation, is already
clearly demonstrated suggesting an important role for Aβ in the
pathogenesis of osteoporosis (Li et al., 2014). This is of great clin-
ical signiﬁcance for providing novel insights into the tight link
between Aβ and human osteoporosis, thus revealing a potential
mechanism underlying altered bone mineral density by Aβ abnor-
mal metabolism. Clearly, however, further work is required to
elucidate the exactmechanisms throughwhichAβ regulates osteo-
porosis signaling. These research efforts may eventually lead to a
promising future discovery of a new etiology for osteoporosis,
and prompt healthcare professionals and researchers to develop
innovative anti-bone-resorptive therapeutic agents and strategies,
particularly those designed by targeting Aβ, to efﬁciently mini-
mize deleterious consequences associated with bone homeostasis
disruption. In linewith these evidence, since a biomarker is a trace-
able substance indicating changes in expression or metabolism
of a given protein which correlates with the risk or progression
of a disease, as consequence, Aβ may be a novel and promising
candidate biomarker for drug targeting and characterization of
osteoporotic therapeutic approaches in the future (Osorio et al.,
2014).
Bone tissue undergoes, throughout life, a continuous renewal
through a process called bone remodeling, which is controlled
by the activity of osteoclasts mediating bone resorption and
parallel activity of osteoblasts which mediate bone formation
(Vacek et al., 2013). Any disturbance in the balanced formation
and resorption process, which can be linked to hormone dis-
equilibrium or aging decreases bone mass and result in bone
pathologies, such as osteoporosis leading to increased vulnerability
to fractures. Within this context, the receptor activator of NF-κB
ligand (RANKL) appears to be an important factor underlying
osteoporosis pathogenesis for its critical role played in osteoclast
differentiation and activation (Park et al., 2014). For this reason,
inhibition of RANKL represents an innovative therapeutic tar-
get for controlling osteoclastogenesis (Park et al., 2011). Notably,
an important role in bone remodeling is played by alternative
or non-canonical NF-κB pathway, which mediates activation of
the p52/RelB NF-κB complex, thus regulating various biologi-
cal processes. This pathway differently from IκBα degradation in
the canonical mechanism, consists of processing of p100 a NF-
κB2 precursor protein,. In this context a central role is played by
NF-κB-inducing kinase (NIK), a component of the non-canonical
NF-κB pathway and a downstream kinase, IKKα (inhibitor of NF-
κB kinase) which operate with integrated functions promoting
induction of phosphorylation-dependent ubiquitination of p100.
Under normal conditions, NIK is processed by a tumor necro-
sis factor (TNF) receptor-associated factor-3 (TRAF3)-dependent
E3 ubiquitin ligase. After signals mediated by a subset of TNF
receptor superfamily members, TRAF3 is degradated and NIK
is stabilized leading to non-canonical activation of NF-κB (Sun,
2012; Figure 3). Accordingly, the inhibitory role of p100, in
both basal and stimulated osteoclastogenesis in bone formation
as well as resorption has been clearly demonstrated (Soysa et al.,
2010). In the alternative NF-κB pathway p52 derived from p100
through NIK, binding of p52 and RelB induces effects on osteo-
clast biology (Soysa et al., 2010). However, to date, the precise
physiologic importance of alternative NF-κB in bone biology, is
not completely elucidated. Furthermore, the currently known
intracellular signaling pathways activated after receptor binding of
RANKL include the nuclear factor of activated T cells (Piva et al.,
2009), mitogen-activated protein kinases (MAPKs), TRAFs, c-Jun
N-terminal kinases (JNKs), and ROS (Kaunitz and Yamaguchi,
2008; Kanzaki et al., 2013). In addition, NF-κB is a transcription
factor, which pleiotropically regulate osteoclast formation, func-
tion, and survival (Piva et al., 2009). Deletion of both NF-κB p50
and p52 subunits is associated to osteopetrosis as consequence
of osteoclast absence and, in addition, NF-κB is central for the
differentiation of RANK-expressing osteoclasts into osteoclasts
TRAP+ induced by osteoclastogenic cytokines. This explain the
inhibitory effect on osteoclast formation induced by prevention
of NF-κB activation (Piva et al., 2009; Augustine and Horwitz,
2013).
Reactive oxygen species act as intracellular signaling molecules
involved in the regulation of RANKL-dependent osteoclast differ-
entiation, but they also have cytotoxic effects that include peroxi-
dation of lipids and oxidative damage to proteins andDNA.Taking
into account the relationship betweenNrf2 and osteoclastogenesis,
stimulation of osteoclast precursors (mouse primary peritoneal
macrophages and RAW 264.7 cells) with RANKL results in the up-
regulation of Keap1, a negative regulator of Nrf2, with decreased
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FIGURE 3 | Canonical and non-canonical pathway leading to the
activation of NF-κB. TRAF3 inhibits activation of the classical NFκB
pathway A high level of TRAF3 interferes with the recruitment of TRAF2
to the receptor. In parallel, TRAF3 induces NIK degradation and
consequently inhibits the activation of the alternative arm of NFκB. The
activation of canonical pathway results in the phosphorylation of IκBαα by
the IKK complex, leading to its ubiquitylation and subsequent degradation
by the proteasome. The RelA/p50 complex is free to translocate to the
nucleus to activate the transcription of target genes. The non-canonical
pathway results in the NIK stabilization. In response to receptor
crosslinking, TRAFs and cIAP1/2 are recruited to the receptor, where
cIAP1/2 ubiquitinates TRAF2 and TRAF3 and stimulates their degradation.
Accumulated NIK activates IKKα, which in turn phosphorylates p100,
leading to p100 processing to p52, which can lead to the activation of
p52-RelB that target distinct κB element and induce the transcription of
target genes.
Nrf2/Keap1 ratio, anddown-regulationof cytoprotective enzymes,
such as heme oxygenase-1 and γ-glutamylcysteine synthetase
(Kanzaki et al., 2013). On the other hand, Nrf2 overexpres-
sion results in up-regulation of the expression of cytoprotective
enzymes, associated with decrease in ROS levels, tartrate-resistant
acid phosphatase-positive multinucleated cell number, as well as
osteoclast differentiation, and attenuation of bone destruction,
as found both in vitro and in vivo models (Kanzaki et al., 2013).
Consistent with this line of evidence, overexpression of Keap1
or RNAi-induced knock-down of Nrf2 resulted in effects oppo-
site to those obtained by stimulation of Nrf2-dependent DNA
binding activity (Kanzaki et al., 2013). The precise mechanisms
by which stimulation with RANKL reduces Nrf2 is not currently
known. It is known Keap1 has highly reactive thiol groups in its
structure and that oxidation of this domain leads to signiﬁcant
changes in the conformation of Keap1, resulting in dissocia-
tion from Nrf2 and stimulation of nuclear Nrf2-dependent DNA
binding activity (Kanzaki et al., 2013). In addition, Nrf2 (see pre-
vious section) autoregulates its own expression (Calabrese et al.,
2010d; Zhang et al., 2011, 2014). Taken together, this evidence
implies that an increase in ROS levels induced by stimulation
with RANKL may up-regulate Nrf2. It has also been reported
that Nrf2 regulates Keap1 by controlling its transcription (Cal-
abrese et al., 2010d; Zhang et al., 2014). Change of stability of
Nrf2 mRNA or decrease of translation by miRNA can modu-
late RANKL-dependent Nrf2 down-regulation. Also, Bach1, an
inhibitor of Nrf2 binding to the ARE, could participate to this
mechanism, as indicated by attenuated osteoclastogenesis found in
Bach1 knock-out mice (Kanzaki et al., 2013). However, although
extensive investigations will be required to clarify the exact reg-
ulatory mechanisms linking Nrf2 to stimulation with RANKL,
it is clearly proven that Keap1/Nrf2 axis regulates RANKL-
dependent osteoclastogenesis through redox-modulation of intra-
cellular ROS signaling and expression of cytoprotective enzymes.
This raises the exciting possibility that the Keap1–Nrf2 axis may
be a therapeutic target for the treatment of bone destructive
disease.
CONCLUSION
Comprehensive evaluation of the biomedical literature has pin-
pointed the role of hormetic dose responses as reported in
essentially all areas of research, including the immune system,
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tumor cell biology, neuroscience, drugs treating osteoporosis,
as well as wound healing and a broad range of receptor sys-
tems and peptides (Calabrese, 2008c, 2013b). Applications of
the hormesis dose response are therefore extensive, affecting
drug discovery, drug development, and the design of the clini-
cal trial. It is now conceivably expected that the hormetic concept
is at the core of attempts leading to enhanced development of
biological shields via processes such as preconditioning which
can help to improve the quality normal living, the aging pro-
cess and to reduce the impact of various types of degenerative
diseases. AD is a chronically progressive disorder, in which neu-
rodegenerative damage progresses for many years before clinical
onset (Calabrese et al., 2006d; Liu and Chan, 2014; Richard and
Brayne, 2014). Osteoporosis is a progressive degenerative disor-
der, also recognizing a multifactorial origin that is characterized
by bone deterioration resulting in fragility and fractures. The
medical and social and economic effects of osteoporosis, given
the increasingly aging population, in particular osteoporosis of
postmenopausal nature, will growth drastically. A better knowl-
edge of bone biology with particular regard to the functional
relationship between bone-formation by osteoblast activity and
bone-resorption by osteoclasts with a better deﬁnition of the
underlying signaling network has unraveled novel therapeutic
targets. Osteoporosis and hip fracture are commonly observed
complications seen in patients with AD. Although the mech-
anisms underlying this association remain poorly understood,
emerging evidence supports the view that AD risk genes may
also be a risk factor for osteoporosis, and that AD and osteo-
porosis may share conserved oxidative stress-driven pathogenic
mechanisms. Consistent with this notion, using transgenic mice
expressing an AD-associated mutant form of APP, known as APP-
swe, to explore the effects of mutant APP on bone remodeling,
signiﬁcant defects in bone formation associated with reduced dif-
ferentiation of bone marrow stromal cells into osteoblasts in ex
vivo culture experiments, were found in these mice compared with
wild-type controls. Treatment with N-acetylcysteine ameliorated
the impact of APPswe on bone marrow stromal cell differen-
tiation, and increased bone volume in these transgenic mice
(Woodman, 2013). Thus, ROS may be a conserved mechanism
underlying APPswe-induced neurodegenerative and osteoporotic
pathological alterations. Bone remodeling is a process of con-
tinuous formation and resorption occurring in speciﬁc areas of
the matrix. Novel therapeutic strategies have been developed
focused on the inhibition of excessive bone resorption and pro-
motion of bone formation process. Due to novel drugs available,
using the most recent knowledge of bone-cell biology, we have
increased our therapeutic intervention to osteoporotic patients
with more individualized lines of treatment. Accordingly, basic
research can greatly contribute to the identiﬁcation of speciﬁc
pathways that can be effectively targeted by novel compounds able
to treat andpossibly reverse osteoporosis, particularly that occur in
already chronically severed patients, such as in neurodegenerative
disorders.
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